Curated News
By: NewsRamp Editorial Staff
December 23, 2025
Oncotelic's Nanomedicine Cuts Drug Side Effects by 67-Fold
TLDR
- Oncotelic Therapeutics' Deciparticle platform offers a competitive edge by enabling intravenous delivery of hydrophobic drugs, potentially improving efficacy and reducing side effects compared to oral dosing.
- The Deciparticle platform works by formulating hydrophobic drugs into uniform nanoparticles for intravenous use, with preclinical data showing reduced gastrointestinal accumulation for Everolimus.
- This nanomedicine technology could make cancer treatments more effective and tolerable, improving patient outcomes and quality of life in immunology and oncology.
- Oncotelic's platform can package water-resistant drugs like macrolide mTOR inhibitors into tiny nanoparticles, a breakthrough that transforms how challenging medications are delivered intravenously.
Impact - Why it Matters
This news matters because it represents a potential leap forward in cancer and immunology treatments. Traditional oral medications like Everolimus often cause severe gastrointestinal issues due to drug accumulation, limiting patient tolerance and effectiveness. By reducing this accumulation by up to 67-fold through intravenous nanomedicine delivery, Oncotelic's technology could significantly improve patient outcomes—allowing for higher, more effective doses with fewer side effects. In oncology, where treatment adherence and quality of life are critical, such advancements could lead to better survival rates and reduced hospitalizations. For the broader medical field, this scalable nanotechnology platform opens doors to reformulating other hard-to-deliver drugs, potentially accelerating development of new therapies for various diseases. Investors and patients alike should watch this space, as it could disrupt current treatment standards and offer new hope where conventional methods fall short.
Summary
Oncotelic Therapeutics (OTCQB: OTLC) is making significant strides in nanomedicine with its Deciparticle™ platform, which reliably formulates diverse hydrophobic drugs—including macrolide mTOR inhibitors, peptides, and polyketides—into uniform, IV-ready nanoparticles. The company's clinical-stage nanomedicine, Sapu Nano, was highlighted at the 2025 San Antonio Breast Cancer Symposium (SABCS), demonstrating the platform's ability to package water-resistant drugs into smaller, uniform nanoparticles suitable for safe intravenous use. This technology shows high compatibility across therapeutic categories, with all five main macrolide mTOR inhibitors—temsirolimus, sirolimus, ridaforolimus, Everolimus (Afinitor®), and umirolimus—forming stable, monodisperse particles, along with key drugs like tacrolimus.
Current preclinical pharmacokinetic data reveal that Sapu003, the intravenous Deciparticle™ formulation of Everolimus (Afinitor®), reduces gastrointestinal drug accumulation by up to 67-fold compared to oral dosing. This breakthrough could transform treatment paradigms in immunology and oncology by enhancing drug delivery efficiency and minimizing side effects. The advancements underscore a rapidly expanding pipeline built on modular, cGMP-ready nanomedicine engineering, positioning Oncotelic Therapeutics as a key player in next-generation drug delivery. For more details, readers can explore the full coverage at ibn.fm/LxQ7N and stay updated through the company's newsroom at ibn.fm/OTLC.
The news was disseminated via BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which focuses on biotechnology and life sciences sectors. BioMedWire provides enhanced press release distribution, social media outreach, and corporate communications solutions to ensure maximum impact for its clients. This platform helps cut through information overload, offering unparalleled recognition and brand awareness for companies like Oncotelic Therapeutics. For further insights, visit BioMedWire or check out the full article at Read More>>.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic's Nanomedicine Cuts Drug Side Effects by 67-Fold
